NEW YORK (GenomeWeb News) – TcLand Expression and Radboud University Nijmegen Medical Center today announced that they will collaborate on looking for biomarkers that predict the effectiveness of drugs for rheumatoid arthritis.
The partners aim to develop a companion diagnostic test for rheumatoid arthritis drugs.
Alessandra Cervino, VP of R&D and biostatistics for Nantes, France-based TcLand Expression, said in a statement that the firm has already developed a test to predict response to rheumatoid arthritis drug infliximab. Now, the firm will work with the researchers at RUNMC to analyze the whole class of anti-TNF drugs.
Further terms of the alliance were not disclosed.